F. Magro

A. Freitas, P. Lago, F. Magro, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Systematic review on drug and diet-induced endoscopic remission in Crohn's disease

F. Magro, P. Pimentel-Nunes, M. Dinis-Ribeiro, 2009, European journal of gastroenterology & hepatology.

Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

S. Ng, C. Lees, C. O'Morain, 2020, Gastroenterology.

Composite outcomes in observational studies of Crohn’s disease: a systematic review and meta-analysis

L. Peyrin-Biroulet, S. Danese, P. Lago, 2022, Therapeutic advances in gastroenterology.

Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis.

L. Peyrin-Biroulet, S. Danese, P. Lago, 2020, Journal of Crohn's & colitis.

Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study

C. O'Morain, V. Andersen, L. Kupčinskas, 2015, Inflammatory bowel diseases.

Phenotype–Genotype Profiles in Crohn's Disease Predicted by Genetic Markers in Autophagy-Related Genes (GOIA Study II)

M. Cravo, J. Cotter, P. Lago, 2013, Inflammatory bowel diseases.

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.

S. Vermeire, G. D'Haens, D. Gaya, 2022, The lancet. Gastroenterology & hepatology.

Dopamine D2 Receptor Polymorphisms in Inflammatory Bowel Disease and the Refractory Response to Treatment

R. Medeiros, F. T. Veloso, F. Magro, 2006, Digestive Diseases and Sciences.

East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort

N. Pedersen, E. Björnsson, V. Andersen, 2013, Gut.

Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis?

F. T. Veloso, F. Magro, P. Pereira, 2005, Inflammatory bowel diseases.

[Portuguese Consensus on the Diagnosis, Prevention and Treatment of Anaemia in Inflammatory Bowel Disease].

A. Gonçalves, P. Lago, F. Magro, 2016, Acta medica portuguesa.

Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease

J. Teixeira, F. Magro, Cristiana Pereira, 2015, Inflammatory bowel diseases.

Interaction between the Renin–Angiotensin System and Enteric Neurotransmission Contributes to Colonic Dysmotility in the TNBS-Induced Model of Colitis

T. Sousa, M. Morato, F. Magro, 2021, International journal of molecular sciences.

The effect of PRR ligands on the membrane potential of intestinal epithelial cells

P. Soares-da-Silva, F. Magro, Diogo Magalhães, 2017, Pharmacological reports : PR.

Short- and long-term regulation of intestinal Na+/H+ exchange by Toll-like receptors TLR4 and TLR5.

J. Cabral, P. Soares-da-Silva, F. Magro, 2015, American journal of physiology. Gastrointestinal and liver physiology.

Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease.

S. Vavricka, M. Høivik, L. Peyrin-Biroulet, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Thiopurines’ Metabolites and Drug Toxicity: A Meta-Analysis

U. Kopylov, L. Peyrin-Biroulet, S. Danese, 2020, Journal of clinical medicine.

Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe--an ECCO-EpiCom study.

N. Pedersen, C. O'Morain, E. Bjornsson, 2014, Journal of Crohn's & colitis.

Impaired synthesis or cellular storage of norepinephrine, dopamine and 5-hydroxytryptamine in inflammatory bowel disease

F. Magro, S. Fraga, M. Vieira-Coelho, 2000, American Journal of Gastroenterology.

Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe An EpiCom study.

V. Andersen, A. Hart, J. Dahlerup, 2011, Journal of Crohn's & colitis.

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

L. Peyrin-Biroulet, W. Reinisch, S. Danese, 2022, Advances in Therapy.

The Impact of SARS-CoV-2 on Inflammatory Bowel Disease

F. Magro, M. M. Estevinho, 2020, GE - Portuguese Journal of Gastroenterology.

Disease course of inflammatory bowel disease unclassified in a European population‐based inception cohort: An Epi‐IBD study

V. Andersen, L. Kupčinskas, S. Sebastian, 2019, Journal of gastroenterology and hepatology.

Impact of Early Surgery and Immunosuppression on Crohn's Disease Disabling Outcomes

J. Cotter, F. Magro, I. Cremers, 2017, Inflammatory bowel diseases.

The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study

V. Andersen, J. Dahlerup, S. Sebastian, 2020, United European gastroenterology journal.

Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.

V. Andersen, J. Dahlerup, M. Friger, 2020, The lancet. Gastroenterology & hepatology.

Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study

C. O'Morain, V. Andersen, L. Kupčinskas, 2018, European journal of gastroenterology & hepatology.

Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort—An ECCO-EpiCom Study

C. O'Morain, V. Andersen, L. Kupčinskas, 2017, Journal of Crohn's & colitis.

Frequency of anaemia and anaemia subtypes in east-west European inception cohort : an ECCO-EpiCom cohort study

V. Andersen, L. Kupčinskas, J. Dahlerup, 2016 .

Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort.

P. Lakatos, P. Munkholm, E. Langholz, 2015, Journal of Crohn's & colitis.

Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort.

L. Kupčinskas, P. Lakatos, P. Munkholm, 2014, Journal of Crohn's & colitis.

Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study.

C. O'Morain, E. Björnsson, V. Andersen, 2014, Journal of Crohn's & colitis.

Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus

J. Gisbert, S. Vermeire, A. Hart, 2019, Digestive Diseases.

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review

L. Peyrin-Biroulet, S. Danese, K. Paridaens, 2022, United European gastroenterology journal.

Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.

G. Macedo, P. Lago, F. Magro, 2020, Inflammatory bowel diseases.

Sexual Quality of Life in Inflammatory Bowel Disease: A Multicenter, National-Level Study.

P. Lago, F. Magro, A. Vieira, 2020, Inflammatory bowel diseases.

A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease

P. Lago, F. Magro, E. Trindade, 2017, Journal of Crohn's & colitis.

Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature.

G. Macedo, F. Magro, A. Sarmento, 2013, Journal of Crohn's & colitis.

Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician

G. Bouma, S. Miehlke, C. Probert, 2018, Journal of gastroenterology and hepatology.

Immunisations in Crohn's disease: who? why? what? when?

F. Magro, C. Abreu, 2014, Best practice & research. Clinical gastroenterology.

Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis

A. Moschen, S. Travis, K. Paridaens, 2021, Scandinavian journal of gastroenterology.

Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease

G. Macedo, F. Carneiro, F. Magro, 2021, Clinical and translational gastroenterology.

Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy.

L. Peyrin-Biroulet, S. Danese, J. Cotter, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology.

L. Peyrin-Biroulet, S. Danese, V. Villanacci, 2020, Journal of Crohn's & colitis.

Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.

L. Peyrin-Biroulet, S. Danese, F. Magro, 2019, The American journal of gastroenterology.

Low Golimumab Trough Levels at Week 6 are Associated with Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.

M. Cravo, P. Lago, F. Magro, 2019, Journal of Crohn's & colitis.

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab

Marco Silva, M. Cravo, P. Lago, 2019, Therapeutic advances in gastroenterology.

Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial

V. Annese, W. Reinisch, S. Danese, 2018, Journal of Crohn's & colitis.

Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus—A Multicenter Retrospective Study

S. Vermeire, M. Ferrante, U. Kopylov, 2017, Inflammatory bowel diseases.

Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis—the ACERTIVE study

F. Dias de Castro, J. Cotter, K. Geboes, 2016, Journal of Crohn's & colitis.

Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.

G. Macedo, K. Geboes, J. Cotter, 2016, Journal of Crohn's & colitis.

The histopathological approach to inflammatory bowel disease: a practice guide

G. Petris, C. Langner, M. Vieth, 2014, Virchows Archiv.

Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

F. Magro, J. Soares, D. Fernandes, 2014, World journal of gastroenterology.

Soluble Selectins, sICAM, sVCAM, and Angiogenic Proteins in Different Activity Groups of Patients with Inflammatory Bowel Disease

F. Magro, F. Araújo, P. Pereira, 2004, Digestive Diseases and Sciences.

Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis.

L. Peyrin-Biroulet, S. Danese, F. Magro, 2022, Inflammatory bowel diseases.

Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

J. Gisbert, E. Savarino, A. Shitrit, 2018, The American Journal of Gastroenterology.

Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?

P. Lago, F. Magro, P. Ministro, 2022, Clinical and translational gastroenterology.

Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey

S. Ng, G. Kaplan, A. Griffiths, 2020, Inflammatory bowel diseases.

DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease.

J. Teixeira, C. Costa, A. Peixoto, 2016, Journal of Crohn's & colitis.

Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.

D. Franchimont, M. Ferrante, L. Peyrin-Biroulet, 2011, Journal of Crohn's & colitis.

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program

M. Dubinsky, M. Regueiro, M. Neurath, 2022, Inflammatory bowel diseases.

Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study.

S. Bonovas, U. Kopylov, S. Sebastian, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Ulcerative colitis in a Southern European country: A national perspective

A. Costa-Pereira, J. Cotter, P. Lago, 2010, Inflammatory bowel diseases.

Clinical practice in Crohn's disease in bordering regions of two countries: different medical options, distinct surgical events.

J. Cotter, P. Lago, F. Magro, 2010, Journal of Crohn's & colitis.

Ulcerative colitis in northern Portugal and Galicia in Spain

J. Cotter, P. Lago, F. Magro, 2010, Inflammatory bowel diseases.

Crohn's disease in a southern European country: Montreal classification and clinical activity

M. Cravo, J. Cotter, P. Lago, 2009, Inflammatory bowel diseases.

Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results

M. Cravo, P. Lago, F. Magro, 2012 .

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study

S. Bonovas, L. Peyrin-Biroulet, G. Fiorino, 2022, United European gastroenterology journal.

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis

S. Vermeire, S. Danese, M. Lukáš, 2020, Journal of Crohn's & colitis.

Clinical trials in ulcerative colitis: a historical perspective.

A. Hart, F. Baert, L. Peyrin-Biroulet, 2015, Journal of Crohn's & colitis.

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

F. Magro, C. Dias, I. Rosa, 2017, Therapeutic advances in gastroenterology.

Clinical performance of an infliximab rapid quantification assay

A. Gonçalves, K. Geboes, P. Lago, 2017, Therapeutic advances in gastroenterology.

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases

E. Louis, D. Rubin, L. Peyrin-Biroulet, 2021, United European gastroenterology journal.

Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?

P. Lago, F. Magro, P. Ministro, 2021, Clinical and translational gastroenterology.

Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence

P. Lago, F. Magro, P. Ministro, 2020, Clinical and translational gastroenterology.

Newborn Congenital Abnormalities and Inflammatory Bowel Disease: Unveiling an Unexplored Relationship.

F. Magro, M. M. Estevinho, 2020, Journal of Crohn's & colitis.

Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal

P. Lago, F. Magro, F. Portela, 2022, GE - Portuguese Journal of Gastroenterology.

Letter to the Editor.

A. Hart, L. Peyrin-Biroulet, S. Danese, 2022, Journal of Crohn's & colitis.

2,4,6-trinitrobenzenesulfonic acid-induced colitis in Rattus norgevicus: a categorization proposal

S. Gonçalves-Monteiro, M. Morato, F. Magro, 2021, Experimental animals.

Clinical prognostic factors for disabling Crohn's disease: a systematic review and meta-analysis.

F. Magro, C. Dias, P. Rodrigues, 2013, World journal of gastroenterology.

Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

J. Gisbert, E. Savarino, T. Molnár, 2021, Journal of clinical medicine.

Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype

F. Rieder, F. Carneiro, I. Gullo, 2021, Clinical and translational gastroenterology.

Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms.

U. Kopylov, R. Eliakim, J. Hanžel, 2021, Journal of Crohn's & colitis.

105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

S. Vermeire, G. D'Haens, D. Gaya, 2021 .

Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial

S. Vermeire, D. Gaya, L. Peyrin-Biroulet, 2020 .

Adenocarcinoma of the cecum as the first manifestation of ulcerative colitis complicated by primary sclerosing cholangitis and endomyocardial fibrosis.

F. Carneiro, F. Magro, M. Dinis-Ribeiro, 2002, Inflammatory bowel diseases.

The tuberculin skin test still matters for the screening of latent Tuberculosis infections among Inflammatory Bowel Disease patients.

F. Magro, A. Sarmento, C. Dias, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Interferon-gamma-induced STAT1-mediated membrane retention of NHE1 and associated proteins ezrin, radixin and moesin in HT-29 cells.

P. Soares-da-Silva, F. Magro, S. Fraga, 2005, Biochemical pharmacology.

Anaemia in Patients with Inflammatory Bowel Disease - A Nationwide Cross-Sectional Study

M. Cravo, J. Cotter, P. Lago, 2016, Digestion.

Increased viability but decreased culturability of Mycobacterium avium subsp. paratuberculosis in macrophages from inflammatory bowel disease patients under Infliximab treatment

R. Appelberg, A. Sarmento, G. Macedo, 2015, Medical Microbiology and Immunology.

Antigenic response to CT‐P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition

João Paulo N. Torres, G. D'Haens, T. Dörner, 2018, Alimentary pharmacology & therapeutics.

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

A. Gonçalves, S. Ben-Horin, P. Lago, 2016, Therapeutic advances in gastroenterology.

Inflammatory Bowel Disease - non-biological treatment.

F. Magro, M. M. Estevinho, Gonçalo Cordeiro, 2020, Pharmacological research.

Colon stenosis in a patient with ulcerative colitis as a manifestation of mixed müllerian tumor of the peritoneum.

J. Lopes, P. Pereira, F. Carneiro, 2005, Scandinavian journal of gastroenterology.

Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels

J. Cotter, K. Geboes, F. Carneiro, 2018, Gut.

The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels

F. Magro, A. Vieira, C. Dias, 2018, Therapeutic advances in gastroenterology.

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays

A. Gonçalves, P. Lago, F. Magro, 2016, Alimentary pharmacology & therapeutics.

Is tofacitinib a game-changing drug for ulcerative colitis?

F. Magro, M. M. Estevinho, 2020, United European gastroenterology journal.

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

L. Peyrin-Biroulet, S. Danese, F. Magro, 2021, Journal of Crohn's & colitis.

Results from the 2 nd Scientific Workshop of the ECCO ( I ) : Impact of mucosal healing on the course of inflammatory bowel disease

D. Franchimont, M. Ferrante, L. Peyrin-Biroulet, 2011 .

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.

C. Langner, A. Hart, R. Eliakim, 2017, Journal of Crohn's & colitis.

Imaging techniques in IBD and their role in follow-up and surveillance

R. Eliakim, F. Magro, 2014, Nature Reviews Gastroenterology &Hepatology.

Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.

J. Stoker, C. Matos, B. Marincek, 2013, Journal of Crohn's & colitis.

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis

L. Peyrin-Biroulet, S. Danese, P. Lago, 2021, United European gastroenterology journal.

F. T. Veloso, F. Magro, J. Carvalho, 1996, Journal of clinical gastroenterology.

Endoscopic balloon dilation of Crohn’s disease strictures-safety, efficacy and clinical impact

T. Baron, G. Macedo, F. Magro, 2017, World journal of gastroenterology.

Cutaneous Morbidity Among Inflammatory Bowel Disease Patients: A Cohort Study

S. Magina, F. Magro, F. Osório, 2018, Journal of Crohn's & colitis.

Metastatic cutaneous Crohn's disease of the face: a case report and review of the literature.

G. Macedo, A. Albuquerque, F. Carneiro, 2011, European journal of gastroenterology & hepatology.

Anti-TNF-Alpha Induced Psoriasiform Eruptions with Severe Scalp Involvement and Alopecia: Report of Five Cases and Review of the Literature

S. Magina, G. Macedo, F. Magro, 2012, Dermatology.

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.

M. Toruner, S. Vavricka, U. Kopylov, 2021, Journal of Crohn's & colitis.

The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease.

C. J. van der Woude, S. Sebastian, C. Selinger, 2015, Journal of Crohn's & colitis.

The daily impact of COVID-19 in gastroenterology

J. Rahier, F. Magro, C. Abreu, 2020, United European gastroenterology journal.

Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).

P. Higgins, H. Sokol, Joel C. Joyce, 2014, Journal of Crohn's & colitis.

Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study

F. Rieux-Laucat, A. Fischer, J. Hugot, 2018, Journal of Crohn's & colitis.

Potassium Channels in Intestinal Epithelial Cells and their Pharmacological Modulation: A Systematic Review.

F. Rieder, F. Magro, D. Cosme, 2020, American journal of physiology. Cell physiology.

Infliximab therapy increases the frequency of circulating CD16+ monocytes and modifies macrophage cytokine response to bacterial infection

R. Appelberg, A. Sarmento, F. Magro, 2014, Clinical and experimental immunology.

Metabolic Inflammation in Inflammatory Bowel Disease: Crosstalk Between Adipose Tissue and Bowel

F. Magro, F. Martel, P. Gonçalves, 2015, Inflammatory bowel diseases.

European consensus on the histopathology of inflammatory bowel disease.

G. Petris, C. Langner, M. Vieth, 2013, Journal of Crohn's & colitis.

Editorial: ulcerative colitis submucosal fibrosis and inflammation: more than just strictures

F. Magro, H. Sousa, 2018, Alimentary pharmacology & therapeutics.

Fibrosis in Ulcerative Colitis

F. Magro, Tatiana António, 2018 .

Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease.

P. Higgins, V. Annese, I. Dotan, 2014, Journal of Crohn's & colitis.

Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies

F. Magro, F. Portela, Fernando Magro, 2010, BioDrugs.

Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties.

L. Peyrin-Biroulet, S. Danese, F. Carneiro, 2020, Journal of Crohn's & colitis.

Gut bacterial microbiome composition and statin intake—A systematic review

F. Magro, L. Figueira, M. Reina-Couto, 2020, Pharmacology research & perspectives.

ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.

L. Stassen, J. Gisbert, O. Zmora, 2019, Journal of Crohn's & colitis.

ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment.

L. Stassen, J. Gisbert, O. Zmora, 2019, Journal of Crohn's & colitis.

An overview on the role of autophagy in cancer therapy

V. Máximo, R. Lima, F. Magro, 2017 .

European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease.

W. Bemelman, P. Higgins, G. Van Assche, 2016, Journal of Crohn's & colitis.

Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort

C. O'Morain, V. Andersen, L. Kupčinskas, 2014, Inflammatory bowel diseases.

Chronic Granulomatous Disease Mimicking Colonic Crohn’s Disease Successfully Treated with Infliximab

A. Peixoto, G. Macedo, F. Magro, 2017, ACG case reports journal.

Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases.

G. Macedo, F. Carneiro, F. Magro, 2015, World journal of gastroenterology.

Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease

M. Morato, F. Magro, Mariana Ferreira-Duarte, 2020, Inflammatory bowel diseases.

Methylation patterns in dysplasia in inflammatory bowel disease patients

A. Peixoto, Marco Silva, P. Lago, 2020, Scandinavian journal of gastroenterology.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis.

S. Vermeire, S. Travis, G. Van Assche, 2012, Journal of Crohn's & colitis.

Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.

G. Macedo, F. Magro, E. Rodrigues-Pinto, 2014, Journal of Crohn's & colitis.

Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn’s disease patients with anastomotic strictures

G. Macedo, F. Magro, P. Andrade, 2017, World journal of gastroenterology.

A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes

F. Magro, Isabel Marcolino da Silva, M. M. Estevinho, 2022, Therapeutic advances in gastroenterology.

New cross-sectional imaging in IBD

F. Magro, H. Sousa, J. Brito, 2018, Current opinion in gastroenterology.

Advanced imaging techniques for small bowel Crohn’s disease: what does the future hold?

F. Magro, I. Pita, 2018, Therapeutic advances in gastroenterology.

Is it Possible to Change Phenotype Progression in Crohn's Disease in the Era of Immunomodulators? Predictive Factors of Phenotype Progression

G. Macedo, F. Magro, Cláudia Camila-Dias, 2014, The American Journal of Gastroenterology.

C. O'Morain, E. Björnsson, V. Andersen, 2014, Journal of Crohn's & colitis.

Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce

A. Hart, S. Vavricka, L. Peyrin-Biroulet, 2020, Journal of Crohn's & colitis.

Correlation Between Calprotectin and Modified Rutgeerts Score

G. Macedo, F. Magro, P. Andrade, 2016, Inflammatory bowel diseases.

Early surgery in Crohn’s disease patients with entero-urinary fistulas: does it change the prognosis?

Marco Silva, G. Macedo, F. Magro, 2016, Scandinavian journal of gastroenterology.

How to manage pouchitis in ulcerative colitis?

F. Magro, S. Rodrigues, I. Azevedo, 2011, Current drug targets.

[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)].

S. Vermeire, S. Travis, G. Van Assche, 2014, Revista de gastroenterologia de Mexico.

Liver abscess of the caudate lobe due to Staphylococcus aureus in an ulcerative colitis patient: First case report.

P. Pereira, G. Macedo, A. Albuquerque, 2011, Journal of Crohn's & colitis.

Mimicry between intestinal Behçet's disease and inflammatory bowel disease.

G. Macedo, F. Magro, J. Guimarães, 2014, Journal of Crohn's & colitis.

Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?

A. Peixoto, F. Magro, R. Coelho, 2019, Current medicinal chemistry.

COVID‐19 in gastroenterology: Where are we now? Current evidence on the impact of COVID‐19 in gastroenterology

A. Nuzzo, K. Pawlak, F. Magro, 2021, United European gastroenterology journal.

Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study

V. Andersen, L. Kupčinskas, S. Sebastian, 2018, Gut.

C-reactive protein in Crohn’s disease: how informative is it?

F. Magro, P. Ministro, P. Sousa, 2014, Expert review of gastroenterology & hepatology.

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease

L. Peyrin-Biroulet, S. Danese, F. Magro, 2023, Therapeutic advances in gastroenterology.

Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

S. Ng, C. O'Morain, A. Griffiths, 2022, The Lancet Gastroenterology & Hepatology.

The timing of early therapeutic strategies has a significant impact on Crohn's disease prognosis.

P. Lago, F. Magro, P. Ministro, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Earlier need of infliximab intensification in ulcerative colitis than in Crohn's disease.

G. Macedo, F. Magro, E. Rodrigues-Pinto, 2014, Journal of Crohn's & colitis.

Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies.

F. Magro, C. Dias, P. Rodrigues, 2015, Journal of Crohn's & colitis.

High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.

Guilherme Macedo, G. Macedo, F. Magro, 2013, Journal of Crohn's & colitis.

Serial Tuberculosis Screening in Inflammatory Bowel Disease Patients Receiving Anti-TNF&agr; Therapy

F. Magro, A. Sarmento, C. Abreu, 2017, Journal of Crohn's & colitis.

Monitoring Crohn’s disease activity: endoscopy, fecal markers and computed tomography enterography

G. Macedo, R. Cunha, F. Magro, 2018, Therapeutic advances in gastroenterology.

Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels.

M. Cravo, F. Dias de Castro, J. Cotter, 2020, Journal of Crohn's & colitis.

The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.

F. Magro, M. M. Estevinho, P. Pinto-Lopes, 2020, Inflammatory bowel diseases.

Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease.

F. Magro, C. Costa, Fernando Magro, 2006, Inflammatory bowel diseases.

Amine neurotransmitters, inflammation and epithelial sodium transport

J. Cabral, P. Soares-da-Silva, F. Magro, 2016, Experimental physiology.

Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake.

P. Soares-da-Silva, F. Magro, S. Fraga, 2004, Acta physiologica Scandinavica.

Effects of NOD2 in intestinal epithelial cells: Cross‐talk between NHE and Na+‐K+‐ATPase activity

J. Cabral, P. Soares-da-Silva, F. Magro, 2015 .

Short- and Long-term Regulation of Intestinal Na+/H+ exchange by TLR4 in intestinal epithelial cells

J. S. Cabral, P. Soares-da-Silva, F. Magro, 2015 .

Short-term effect on intestinal epithelial Na(+)/H(+) exchanger by Gi(alpha1,2)-coupled 5-HT(1A) and G(q/11)-coupled 5-HT(2) receptors.

P. Soares-da-Silva, F. Magro, S. Fraga, 2007, Life sciences.

Intestinal Na+–K+–ATPase activity and molecular events downstream of interferon‐γ receptor stimulation

P. Soares-da-Silva, F. Magro, S. Fraga, 2004, British journal of pharmacology.

Intestinal 5-Hydroxytryptamine and Mast Cell Infiltration in Rat Experimental Colitis

P. Soares-da-Silva, F. Magro, S. Fraga, 2006, Digestive Diseases and Sciences.

Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab

S. Danese, J. Fonseca, F. Magro, 2020, BioDrugs.

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients

A. Hart, L. Peyrin-Biroulet, S. Danese, 2023, Medicina.

Prospective study of blood viral load of Epstein-Barr virus, herpes virus type 6 and human parvovirus B19 in Crohn's disease: Does therapy matter?

F. Magro, A. Sarmento, C. Dias, 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Epstein–Barr Virus in Inflammatory Bowel Disease—Correlation with Different Therapeutic Regimens

A. Sarmento, A. Albuquerque, J. Cabral, 2013, Inflammatory bowel diseases.

Disseminated cutaneous herpes simplex infection in a patient with Crohn's disease under azathioprine and steroids: First case report and literature review.

G. Macedo, F. Magro, P. Andrade, 2014, Journal of Crohn's & colitis.

Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial

M. Severo, I. Paciência, A. Moreira, 2021, Porto biomedical journal.

P545 Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition

G. D'Haens, T. Dörner, G. Fiorino, 2018 .

Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study

P. Lago, F. Magro, P. Ministro, 2020, Therapeutic advances in gastroenterology.

What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale

P. Lago, F. Magro, P. Ministro, 2019, Therapeutic advances in gastroenterology.

A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays

F. Magro, P. Pinto-Lopes, J. Afonso, 2016, Inflammatory bowel diseases.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword.

F. Magro, 2010, BioDrugs.

Foreword

F. Magro, 2010, BioDrugs.

Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review.

L. Peyrin-Biroulet, P. Lago, F. Magro, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis

L. Peyrin-Biroulet, S. Danese, V. Jairath, 2023, United European gastroenterology journal.

Accuracy of the new rapid test for monitoring adalimumab levels

P. Lago, F. Magro, A. Vieira, 2019, Therapeutic advances in gastroenterology.

Toxic Megacolon as an Inaugural Manifestation of Ulcerative Colitis

P. Pereira, G. Macedo, A. Albuquerque, 2011 .

Gingival Hyperplasia as a First Manifestation of Crohn's Disease

F. Carneiro, F. Magro, R. Correia, 2005, Digestive Diseases and Sciences.

Looking into Enteric Virome in Patients with IBD: Defining Guilty or Innocence?

G. Macedo, F. Carneiro, F. Magro, 2017, Inflammatory bowel diseases.

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease

R. Marinho, F. Magro, P. Ministro, 2022, United European gastroenterology journal.

The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review.

P. Lago, F. Magro, P. Ministro, 2022, Inflammatory bowel diseases.

M. Cravo, J. Cotter, F. Magro, 2019, Digestion.

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization

S. Vavricka, L. Peyrin-Biroulet, S. Danese, 2020, Gastroenterology.

Short Inflammatory Bowel Disease Questionnaire: translation and validation to the Portuguese language

F. Magro, A. Marreiros, H. Sousa, 2021, Health and Quality of Life Outcomes.

Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays

P. Lago, F. Magro, A. Vieira, 2020, Therapeutic advances in gastroenterology.

Aminosalicylates and COVID-19: Facts or Coincidences?

M. Morato, F. Magro, C. Dias, 2020, Gastroenterology.

Placebo Effect on the Health-related Quality of Life of Inflammatory Bowel Disease Patients: A Systematic Review With Meta-analysis

P. Lago, F. Magro, E. Trindade, 2018, Journal of Crohn's & colitis.

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation

A. Gonçalves, K. Geboes, P. Lago, 2017, EBioMedicine.

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study

V. Andersen, L. Kupčinskas, S. Sebastian, 2018, Journal of Crohn's & colitis.

P694 Disease course during the first five years following diagnosis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort.

L. Kupčinskas, J. Dahlerup, P. Lakatos, 2017, Journal of Crohn's & colitis.

Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group.

S. Bonovas, A. Hart, E. Vegni, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Anti-TNF treatment failure: drug levels, immunogenicity, or both?

F. Magro, 2019, The lancet. Gastroenterology & hepatology.

P229 The new biosimilar of infliximab SB2 can be quantified by IFX-optimised therapeutic drug monitoring assays

F. Magro, A. Vieira, C. Dias, 2018 .

Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus.

A. Hart, L. Peyrin-Biroulet, S. Danese, 2021, Autoimmunity reviews.

Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

P. Lakatos, S. Danese, S. Ben-Horin, 2018, Alimentary pharmacology & therapeutics.

823 Fecal Calprotectin Levels, C-Reactive Protein Levels, and Partial Mayo Score as Early Predictors of Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Treated With Tofacitinib in a Phase 2 Study

M. Dubinsky, D. Hudesman, F. Magro, 2019, American Journal of Gastroenterology.

Signaling of short‐ and long‐term regulation of intestinal epithelial type 1 Na+/H+ exchanger by interferon‐γ

P. Soares-da-Silva, F. Magro, S. Fraga, 2005, British Journal of Pharmacology.

Refractory monogenic Crohn’s disease due to X-linked inhibitor of apoptosis deficiency

S. Magina, A. Peixoto, G. Macedo, 2016, International Journal of Colorectal Disease.

Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative Colitis

S. Vermeire, J. L. Costa, I. Cleynen, 2020, Clinical and translational gastroenterology.

Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients.

F. Magro, A. Sarmento, C. Abreu, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries

F. Mearin, S. Danese, É. Lerebours, 2013, European journal of gastroenterology & hepatology.

Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach

P. Gionchetti, S. Sebastian, L. Peyrin-Biroulet, 2018, Digestive Diseases.

Increased viability but decreased culturability of Mycobacterium avium subsp. paratuberculosis in macrophages from inflammatory bowel disease patients under Infliximab treatment

R. Appelberg, A. Sarmento, G. Macedo, 2015, Medical Microbiology and Immunology.

Case series: ulcerative colitis, multiple sclerosis, and interferon-beta 1a.

G. Macedo, F. Magro, M. Marques, 2010, Inflammatory bowel diseases.

Prevalence of Mycobacteriumavium subsp. paratuberculosis and Escherichia coli in blood samples from patients with inflammatory bowel disease

R. Appelberg, A. Sarmento, T. Bull, 2015, Medical Microbiology and Immunology.

Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision

Rogério Sá Gaspar, Beatriz Silva-Lima, Fernando Magro, 2020, Frontiers in Medicine.

Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease

V. Annese, J. Teixeira, A. Peixoto, 2017, PloS one.

CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.

M. Silverberg, W. Bemelman, M. Dubinsky, 2022, Gastroenterology.

P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn’s disease: results up to Week 48 of the STARDUST trial

S. Vermeire, G. D'Haens, D. Gaya, 2021 .

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis

A. Hart, L. Peyrin-Biroulet, S. Danese, 2023, Journal of clinical medicine.

Comparison of the Nancy index with continuous Geboes score: histological remission and response in ulcerative colitis.

J. Cotter, K. Geboes, F. Carneiro, 2020, Journal of Crohn's & colitis.

Oral squamous cell carcinoma in a Crohn's disease patient taking azathioprine: case report and review of the literature.

F. Beca, C. Eloy, J. Lopes, 2012, Journal of Crohn's & colitis.

AB0891 Prevalence of Osteoporosis and Vitamin D Deficiency in Patients with Inflammatory Bowel Disease

Ana Sofia Brás Pinto, F. Magro, M. Bernardes, 2015 .

Gastroenterological features of COVID-19 and the role of the United European Gastroenterology Journal

J. Drenth, F. Magro, 2020, United European gastroenterology journal.

ECCO Position on harmonization of Crohn's disease mucosal histopathology.

L. Peyrin-Biroulet, S. Danese, J. Sabino, 2022, Journal of Crohn's & colitis.

P395 Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease

N. Harpaz, W. Reinisch, B. Feagan, 2021 .

Is Faecal Calprotectin Important in Detecting Silent Gut Inflammation in Seronegative Arthropathies?

F. Magro, M. M. Estevinho, M. Estevinho, 2020, Journal of Crohn's & colitis.

Varicella Complicated by Severe Pneumonia and Shock in an Immunosuppressed Crohn's Disease Patient Under Azathioprine and Anti-Tumour Necrosis Factor Alpha.

F. Magro, C. Abreu, L. Santos, 2015, Journal of Crohn's & colitis.

Viable Mycobacterium avium subsp. paratuberculosis Colonizes Peripheral Blood of Inflammatory Bowel Disease Patients

A. Sarmento, T. Bull, F. Magro, 2023, Microorganisms.

Disabling and Reoperation in Patients with Crohn's Disease Subject to Early Surgery or Immunosuppression: A Bayesian Network Prognostic Model

Pedro Pereira Rodrigues, Cláudia Camila Dias, Fernando Magro, 2016, 2016 IEEE 29th International Symposium on Computer-Based Medical Systems (CBMS).

Preliminary Study for a Bayesian Network Prognostic Model for Crohn's Disease

Pedro Pereira Rodrigues, Cláudia Camila Dias, Fernando Magro, 2015, 2015 IEEE 28th International Symposium on Computer-Based Medical Systems.

Dysplasia surveillance in an ulcerative colitis patient: successful detection with narrow band imaging and magnification.

P. Pereira, G. Macedo, F. Carneiro, 2011, Journal of Crohn's & colitis.

Severe gram positive bacterial infection in an ulcerative colitis patient treated with Infliximab.

F. Magro, M. Marques, S. Rodrigues, 2010, Journal of Crohn's & colitis.

Reintroduction of Anti-TNFα Therapy After (or even During) Anti-TNFα-associated Tuberculosis in Immune-mediated Diseases.

F. Magro, A. Sarmento, C. Abreu, 2016, Journal of Crohn's & colitis.

Do Neutrophils Contribute to Development of Crohn's Disease and Ulcerative Colitis?"

F. Magro, M. M. Estevinho, M. Estevinho, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

How to Evaluate Fibrosis in IBD?

F. Magro, H. Tavares de Sousa, 2023, Diagnostics.

Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.

D. Rubin, L. Peyrin-Biroulet, I. Dotan, 2022, The lancet. Gastroenterology & hepatology.

Inflammatory Bowel Disease in Migrant Populations: Should we look Even Further Back?

G. Fiorino, S. Danese, M. Allocca, 2021, Current drug targets.

The who-when-why triangle of CAM use among Portuguese IBD patients.

M. Cravo, P. Lago, F. Magro, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bile salts and proinflammatory cytokines inhibit MCT1-mediated cellular uptake of butyrate and interfere with its antiproliferative properties.

F. Magro, M. Couto, F. Martel, 2023, Experimental cell research.

Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort Study

F. Magro, A. Sarmento, C. Abreu, 2023, Vaccines.

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis

A. Moschen, S. Travis, K. Paridaens, 2022, Intestinal research.

P478 Thiopurines’ metabolites levels and drug toxicity: a systematic review and meta-analysis

F. Magro, P. Ministro, C. Dias, 2020 .

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial

S. Vermeire, G. D'Haens, D. Gaya, 2023, United European gastroenterology journal.

Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab

S. Danese, J. Fonseca, F. Magro, 2020, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Mycobacterium avium SPP. Paratuberculosis up-regulates CD40 expression and down-regulates IL-10 production by human macrophages

A. Sarmento, Joana Cabral, F. Magro, 2009 .

Transmural healing in Crohn's disease: Beyond mural findings.

R. Cunha, F. Magro, P. Andrade, 2018, Digestive and Liver Disease.

Whipple's disease and giardiasis, An uncommon association

G. Macedo, A. Albuquerque, F. Magro, 2012 .

Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis : Definitions and diagnosis

S. Travis, R. Eliakim, J. Lindsay, 2012 .

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes

L. Peyrin-Biroulet, F. Rieder, V. Jairath, 2023, Journal of Crohn's & colitis.

[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)].

S. Vermeire, S. Travis, R. Eliakim, 2014, Revista de gastroenterologia de Mexico.

Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.

C. O'Morain, A. Griffiths, L. Peyrin-Biroulet, 2023, The lancet. Gastroenterology & hepatology.

I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease.

J. Gisbert, T. Molnár, F. Baert, 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Corrigendum to: Diagnostic Yield of Next-Generation Sequencing in Very Early-Onset Inflammatory Bowel Diseases: A Multicenter Study

F. Rieux-Laucat, A. Fischer, J. Hugot, 2020, Journal of Crohn's & Colitis.

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study

L. Peyrin-Biroulet, S. Danese, P. Lago, 2023, United European Gastroenterology journal.

Ionizing radiation exposure is still increasing in Crohn’s disease: Who should be blamed?

A. Peixoto, Marco Silva, G. Macedo, 2015, Scandinavian journal of gastroenterology.

Dipeptidyl peptidase 4 (DPP4) in fecal samples: validation of the extraction methodology and stability in short-term storage conditions

F. Magro, C. Dias, Francisco J Melo, 2023, Clinical chemistry and laboratory medicine.

Taurocholate uptake by Caco-2 cells is inhibited by pro-inflammatory cytokines and butyrate.

F. Magro, M. Couto, F. Martel, 2023, Cytokine.